PRISM BioLab Co.,LTD (TYO:206A)

Japan flag Japan · Delayed Price · Currency is JPY
193.00
+2.00 (1.05%)
At close: Mar 6, 2026
Market Cap7.13B -30.7%
Revenue (ttm)684.61M +83.8%
Net Income-927.75M
EPS-25.26
Shares Out36.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume292,800
Average Volume591,205
Open186.00
Previous Close191.00
Day's Range186.00 - 197.00
52-Week Range132.00 - 315.00
Betan/a
RSI48.71
Earnings DateFeb 13, 2026

About PRISM BioLab Co.,LTD

PRISM BioLab Co.,LTD engages in the research and development of pharmaceuticals using its proprietary drug discovery platform technology, PepMetics Technology. It develops E7386 targeting CBP/beta-catenin, which is in Phase II clinical trial for the treatment of cancer; and PRI724 targeting CBP/beta-catenin that is in Phase II clinical trial for treating cirrhosis. The company was founded in 2006 and is based in Fujisawa, treating Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 35
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 206A
Full Company Profile

Financial Performance

In fiscal year 2025, PRISM BioLab Co.,LTD's revenue was 677.33 million, an increase of 121.62% compared to the previous year's 305.62 million. Losses were -833.70 million, -20.56% less than in 2024.

Financial Statements